Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on NVCR stock, giving a Buy rating today.Don't Miss our Black Friday ...
Novocure price target raised to $38 from $30 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $38 from $30 and keeps a Buy rating on the shares after the company ...
bovnews3h
Hut 8 Corp (HUT) Stock Settles at $28.37: What’s Contributing to This Price Point?
On Friday, Hut 8 Corp (HUT) stock saw a decline, ending the day at $28.37 which represents a decrease of $-0.08 or -0.28% from the prior close of $28.45. The stock opened at $28.45 and touched a low ...
Stocktwits on MSN3h
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...
bovnews7h
Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright
H.C. Wainwright has recently raised Syros Pharmaceuticals Inc (SYRS) stock to Buy rating, as announced on November 4, 2020, according to Finviz. Earlier, on September 22, 2020, Alliance Global ...
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Thanks to the Securities and Exchange Commission, you don't have to. Artificial intelligence (AI) has been the stock market's ...
manilatimes16h
Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 ...